Autolus Therapeutics plc (6A3A) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.378x

Based on the latest financial reports, Autolus Therapeutics plc (6A3A) has a cash flow conversion efficiency ratio of -0.378x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-67.32 Million ≈ $-78.71 Million USD) by net assets (€178.13 Million ≈ $208.25 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Autolus Therapeutics plc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.

Autolus Therapeutics plc - Cash Flow Conversion Efficiency Trend (2017–2025)

This chart illustrates how Autolus Therapeutics plc's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Autolus Therapeutics plc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Autolus Therapeutics plc ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Logan Energy Corp V:LGN	0.019x
Hubei Guochuang Hi-tech Material Co Ltd SHE:002377	-0.083x
JiangXi BaiSheng Intelligent Technology Co. Ltd. SHE:301083	N/A
Reckitt Benckiser Group PLC LSE:RKT	0.191x
Hanil Cement Co Ltd KO:003300	0.040x
Haleon PLC LSE:HLN	0.032x
Hotel Majestic Cannes PA:MLHMC	0.033x
Beijing Dynamic Power Co Ltd SHG:600405	-4.892x

Annual Cash Flow Conversion Efficiency for Autolus Therapeutics plc (2017–2025)

The table below shows the annual cash flow conversion efficiency of Autolus Therapeutics plc from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see 6A3A company net worth.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	€178.13 Million ≈ $208.25 Million	€-283.57 Million ≈ $-331.52 Million	-1.592x	-229.79%
2024-12-31	€427.32 Million ≈ $499.59 Million	€-206.27 Million ≈ $-241.15 Million	-0.483x	+63.04%
2023-12-31	€111.47 Million ≈ $130.32 Million	€-145.59 Million ≈ $-170.21 Million	-1.306x	-247.32%
2022-12-31	€298.67 Million ≈ $349.18 Million	€-112.31 Million ≈ $-131.30 Million	-0.376x	+0.04%
2021-12-31	€313.32 Million ≈ $366.30 Million	€-117.86 Million ≈ $-137.79 Million	-0.376x	+32.91%
2020-12-31	€210.03 Million ≈ $245.55 Million	€-117.76 Million ≈ $-137.67 Million	-0.561x	-40.79%
2019-12-31	€254.84 Million ≈ $297.93 Million	€-101.48 Million ≈ $-118.65 Million	-0.398x	-139.23%
2018-12-31	€255.47 Million ≈ $298.67 Million	€-42.52 Million ≈ $-49.72 Million	-0.166x	-45.09%
2017-12-31	€142.60 Million ≈ $166.72 Million	€-16.36 Million ≈ $-19.13 Million	-0.115x	--

About Autolus Therapeutics plc

F:6A3A Germany Biotechnology

Market Cap

$413.83 Million

€353.97 Million EUR

Market Cap Rank

#14030 Global

#1415 in Germany

Share Price

€1.33

Change (1 day)

+4.72%

52-Week Range

€1.06 - €2.24

All Time High

€40.10